Next Article in Journal
Glioma Specific Extracellular Missense Mutations in the First Cysteine Rich Region of Epidermal Growth Factor Receptor (EGFR) Initiate Ligand Independent Activation
Next Article in Special Issue
Inferences for the Lead Time in Breast Cancer Screening Trials under a Stable Disease Model
Previous Article in Journal
Common Altered Epigenomic Domains in Cancer Cells: Characterization and Subtle Variations
Previous Article in Special Issue
Neuropilins: A New Target for Cancer Therapy
Article Menu

Export Article

Open AccessReview
Cancers 2011, 3(2), 2014-2031;

EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab’s Clinical Effects

Center of Molecular Immunology, P.O. Box 16040, Havana 11600, Cuba
Author to whom correspondence should be addressed.
Received: 4 February 2011 / Revised: 19 March 2011 / Accepted: 24 March 2011 / Published: 18 April 2011
(This article belongs to the Special Issue Cancer Diagnosis and Targeted Therapy)
Full-Text   |   PDF [615 KB, uploaded 18 April 2011]


Current clinical trials of epidermal growth factor receptor (EGFR)-targeted therapies are mostly guided by a classical approach coming from the cytotoxic paradigm. The predominant view is that the efficacy of EGFR antagonists correlates with skin rash toxicity and induction of objective clinical response. Clinical benefit from EGFR-targeted therapies is well documented; however, chronic use in advanced cancer patients has been limited due to cumulative and chemotherapy-enhanced toxicity. Here we analyze different pieces of data from mechanistic and clinical studies with the anti-EGFR monoclonal antibody Nimotuzumab, which provides several clues to understand how this antibody may induce a biological control of tumor growth while keeping a low toxicity profile. Based on these results and the current state of the art on EGFR-targeted therapies, we discuss the need to evaluate new therapeutic approaches using anti-EGFR agents, which would have the potential of transforming advanced cancer into a long-term controlled chronic disease. View Full-Text
Keywords: EGFR; Nimotuzumab; cancer treatment; targeted therapy; biological therapy EGFR; Nimotuzumab; cancer treatment; targeted therapy; biological therapy
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Perez, R.; Moreno, E.; Garrido, G.; Crombet, T. EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab’s Clinical Effects. Cancers 2011, 3, 2014-2031.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top